Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer
Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.
Weekly Dose-Dense Chemotherapy Not Superior to Standard of Care in Epithelial Ovarian Cancer
September 21st 2020Weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer when it comes to progression-free survival and overall survival, though the regimen is safe and effective.
Frontline fulvestrant in combination with palbociclib demonstrated an improvement in progression-free survival at 1 year compared with fulvestrant and placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2-negative metastatic breast cancer, which met the primary end point of the phase 2 FLIPPER trial.
Pembrolizumab/Chemo Combo Represents New Frontline Standard in Advanced Esophageal Cancer
Frontline pembrolizumab plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rates compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer.
Tucatinib Regimen Maintains Health-Related QoL in HER2+ Metastatic Breast Cancer
September 21st 2020The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.
Frontline Ipatasertib/Abiraterone Regimen Shows Superior Radiographic PFS in PTEN-Loss mCRPC
Ipatasertib combined with abiraterone acetate plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity compared with placebo plus abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer with PTEN loss.
Long-Term Follow-Up Shows Encouraging OS With Enfortumab Vedotin in Urothelial Carcinoma
Long-term follow-up of patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin monotherapy showed encouraging results, with half of patients still alive at 12 months and approximately one-third alive at 18 months.
Surufatinib Improves PFS in Advanced Pancreatic NETs
September 20th 2020The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.
Dr. Johnston on the Results of monarchE With Abemaciclib in High-Risk Early Breast Cancer
September 20th 2020Stephen Johnston, MA, PhD, FRCP, discusses the results of the phase 3 monarchE study examining the addition of abemaciclib to endocrine therapy in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.
Regorafenib Showed Modest Activity in Ewing Sarcoma
Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.
Updated Findings Show Olaparib Prolongs OS in Men with mCRPC
September 20th 2020Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.
EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC
September 20th 2020The combination of amivantamab and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib-resistant patients with advanced EGFR-mutant non–small cell lung cancer.
First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC
September 20th 2020Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival.
DART Molecule MGD019 Displays Monotherapy Efficacy in Heavily Pretreated Solid Tumors
September 20th 2020An acceptable safety profile coupled with pharmacokinetic and pharmacodynamic data for the DART molecule MGD019 were reported during the European Society for Medical Oncology Virtual Congress 2020 from results of a first-in-human study.
Sotorasib Shows Encouraging Antitumor Activity in Advanced NSCLC
September 20th 2020The investigational drug sotorasib demonstrated promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation, an aberration for which no targeted treatment has yet been approved.
Overall survival benefits of frontline maintenance treatment with avelumab in patients with advanced urothelial cancer were found to be positively associated with biomarkers of immune activity and negativity linked with biomarkers of tumor homeostasis and chronic inflammation.
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial
September 20th 2020Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Abemaciclib Reduces the Risk of Recurrence in High-Risk Early Breast Cancer
September 20th 2020The addition of abemaciclib to endocrine therapy led to a significant reduction in the risk of invasive disease versus endocrine therapy alone in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.
PORT Not Recommended as Standard of Care in Completely Resected Stage IIIAN2 NSCLC
September 20th 2020Post-operative radiotherapy was linked with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non–small cell lung cancer and thus cannot be recommended as a standard of care for this population.